GlobeNewsWire
25 Aug 2026, 16:50 UTC · 5h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
An FDA advisory committee voted 9-3 that available evidence does not support the efficacy of Capricor's deramiocel for treating DMD-associated cardiomyopathy. — A negative advisory committee vote significantly reduces the probability of FDA approval for a lead drug candidate, directly impacting future revenue potential.
-0.90The FDA criticized Capricor's data measurement methods, stating the conversion of raw change to percent change and back was not scientifically justified. — Questions regarding data integrity and scientific justification can lead to regulatory rejection and erode investor trust in company reporting.
-0.70A class action lawsuit has been filed alleging that Capricor made misleading statements and failed to disclose unauthorized changes to its statistical analysis plan. — Securities litigation creates financial liability and suggests systemic governance or transparency issues within the company.
-0.40Continue reading
6 related stories
Top 1 mover · tap to explore
Which stocks this story touches
The company is facing a securities fraud class action lawsuit following FDA concerns over data integrity and a negative advisory committee vote on its lead drug candidate.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
54m ago
